Đang chuẩn bị liên kết để tải về tài liệu:
báo cáo hóa học:" CTLA4 blockade increases Th17 cells in patients with metastatic melanoma"

Tuyển tập các báo cáo nghiên cứu về hóa học được đăng trên tạp chí sinh học quốc tế đề tài : CTLA4 blockade increases Th17 cells in patients with metastatic melanoma | Journal of Translational Medicine BioMed Central Research CTLA4 blockade increases Thl7 cells in patients with metastatic melanoma Erika von Euw1 Thinle Chodon2 Narsis Attar2 Jason Jalil1 Richard C Koya1 Begonya Comin-Anduix1 and Antoni Ribas 1 2 3 Open Access Address Department of Surgery Division of Surgical Oncology University of California Los Angeles UCLA Los Angeles California USA 2Department of Medicine Division of Hematology Oncology UCLA Los Angeles California USA and 3Jonsson Comprehensive Cancer Center UCLA Los Angeles California USA Email Erika von Euw - erivoneuw@yahoo.com.ar Thinle Chodon - tchodon@mednet.ucla.edu Narsis Attar - nattar@mednet.ucla.edu Jason Jalil - jjalil@ucla.edu Richard C Koya-rkoya@mednet.ucla.edu Begonya Comin-Anduix-bcomin@mednet.ucla.edu Antoni Ribas - aribas@mednet.ucla.edu Corresponding author Published 20 May 2009 Received 18 February 2009 Journal of Translational Medicine 2009 7 35 doi l0.ll86 l479-5876-7-35 Accepted 20 May 2009 This article is available from http www.translational-medicine.cOm content 7 1 35 2009 von Euw et al licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License http creativecommons.org licenses by 2.0 which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Abstract Background Th 17 cells are CD4 cells that produce interleukin 17 IL-17 and are potent inducers of tissue inflammation and autoimmunity. We studied the levels of this T cell subset in peripheral blood of patients treated with the anti-CTLA4 antibody tremelimumab since its major dose limiting toxicities are inflammatory and autoimmune in nature. Methods Peripheral blood mononuclear cells PBMC were collected before and after receiving tremelimumab within two clinical trials one with tremelimumab alone 21 patients and another together with autologous dendritic cells DC pulsed with the melanoma epitope .